

Rev05  
 Update: Aug,11,2025
**DATASHEET**

# PEDF, Human

Cat. No.: Z02722

## Product Introduction

|                                     |                                                                                                                                                                                                                                                                                      |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Species</b>                      | Human                                                                                                                                                                                                                                                                                |
| <b>Protein Construction</b>         | <b>PEDF (Gln20-Pro418)<br/>Accession # P36955</b>                                                                                                                                                                                                                                    |
| <b>Purity</b>                       | > 97% as analyzed by SDS-PAGE<br>> 97% as analyzed by HPLC                                                                                                                                                                                                                           |
| <b>Endotoxin Level</b>              | < 1 EU/μg of protein by LAL method                                                                                                                                                                                                                                                   |
| <b>Biological Activity</b>          | Fully biologically active when compared to standard. The ED <sub>50</sub> as determined by its ability to enhance the adhesion of human Saos2 cells to bovine Collagen I coated plate is less than 2.0 ng/ml, corresponding to a specific activity of > 5.0 × 10 <sup>5</sup> IU/mg. |
| <b>Expression System</b>            | E. coli                                                                                                                                                                                                                                                                              |
| <b>Theoretical Molecular Weight</b> | 44.4 kDa                                                                                                                                                                                                                                                                             |
| <b>Formulation</b>                  | Lyophilized from a 0.2 μm filtered solution in 20 mM PB, pH 7.4, 150 mM NaCl.                                                                                                                                                                                                        |
| <b>Reconstitution</b>               | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml.                             |
| <b>Storage &amp; Stability</b>      | Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.                                                           |

## Background

**Target Background :** PEDF is a noninhibitory serpin with neurotrophic, anti-angiogenic, and anti-tumorigenic properties. It is a 50 kDa glycoprotein produced and secreted in many tissues throughout the body. A major component of the anti-angiogenic action of PEDF is the induction of apoptosis in proliferating endothelial cells. In addition, PEDF is able to inhibit the activity of angiogenic factors such as VEGF and FGF-2. The neuroprotective effects of PEDF are achieved through suppression of neuronal apoptosis induced by peroxide, glutamate, or other neurotoxins. The recent identification of a lipase-linked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity should facilitate further elucidation of the underlying mechanisms of this pluripotent serpin. To date, PEDF-R is the only signaling receptor known to be used by a serpin family member. The unique range of PEDF activities implicate it as a potential therapeutic agent for the treatment of vasculature related neurodegenerative diseases such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). PEDF also has the potential to be useful in the treatment of various angiogenesis-related diseases including a number of cancers.

**Synonyms :** SERPINF1; EPC-1; OI12; OI6; PEDF; PIG35; serpin family F member 1; Pigment epithelium-derived factor

**For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.**

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China